FIGHTING TO IMPROVE
DIAGNOSIS AND TREATMENT OF SYSTEMIC AMYLOID DISEASES (NON-CNS)
Aurora Bio is a clinical-stage biotechnology company focused on amyloidosis, including novel diagnostics and therapeutics. We are fighting to improve the lives of patients suffering from systemic amyloid diseases such as light chain (AL), transthyretin (ATTR), and LECT2 amyloidosis
At Aurora Bio, we aim to improve the diagnosis and treatment of systemic amyloid diseases to increase patient survival and quality of life. Our approach allows us to target all forms of systemic amyloid diseases with the same underlying technology.
We are developing a peptide-based technology platform that facilitate a diagnostic and disease monitoring agent and novel immunotherapies designed to clear amyloid fibrils in patients with systemic amyloid diseases. Our diagnostic and therapeutic targets provide a platform for detecting, targeting and clearing systemic amyloid.
AURORA BIO IS LEADING THE WAY TO DISCOVER NEW APPROACHES TO SYSTEMIC AMYLOIDOSIS
“FIRST-IN-CLASS” IMAGING AGENT AND THERAPEUTIC OPTIONS FOR SYSTEMIC AMYLOIDOSIS
Headquartered in San Francisco and founded in 2019, Aurora is a clinical-stage biotech company developing a peptide-based platform technology including the development of an imaging agent and immunotherapies for systemic amyloid diseases.
The Company’s lead asset, P5+14, is a novel imaging agent that is in Phase 1 clinical trials and is positioned to be the first approved diagnostic specifically for amyloidosis.
Early phase 1 data shows excellent binding and imaging properties for the 3 most common systemic amyloid diseases: transthyretin, light chain, and LECT2 Amyloidosis.
Aurora Bio is developing peptide-based immunotherapies and cell therapy that targets phagocytosis of amyloid deposits leveraging the exquisite binding properties of our peptide technology. Aurora’s technology has broad applications and the potential to address up to 30 systemic amyloid based diseases.
AMYLOID TARGETED IMMUNOTHERAPY
Reduction of amyloid is a validated target in systemic amyloidosis. Three therapies have been recently approved for ATTR amyloidosis that target reduction or stabilization of the pre-cursor protein. By limiting production of amyloid, these therapies have led to better patient outcomes.
Aurora Bio has a different but complementary approach. While therapies targeting precursor protein may reduce future amyloid production, they do not directly address the toxic fibrils that are infiltrating tissues and organs. We believe direct targeting will remove injury to tissues being destroyed by amyloid. This approach may have benefit in each stage of a patients disease, including later stage patients where current ATTR therapies have not shown benefit. In addition, this approach would be complementary to current treatments by attacking both sides of the problem, as normal clearance is impaired in amyloidosis patients.
Aurora Bio has the therapeutic potential to address up to 30 diseases. 29 out of 30 systemic amyloid diseases do not have approved therapies, and 28 out of 30 have no therapies in development. Our peptide technology has unprecedented binding to all types of systemic amyloid. We are developing three therapeutic approaches based on this technology.